Epirubicin cardiotoxicity: a study of 135 patients with advanced breast cancer.

• DOI: 10.1200/jco.1990.8.11.1806
• Publication Date: 2017-02-23T18:12:31Z
• Authors: D Nielsen; J B Jensen; P Dombernowsky; O Munck; J Fogh; I Brynjolf; H Havsteen; M Hansen
• Keywords: Cardiotoxicity; Epirubicin; Cumulative dose; Cumulative incidence

The cardiotoxicity of epirubicin (EPI) was evaluated clinically, radiologically, with ECG, and multiple ECG-gated radionuclide determination the left ventricular ejection fraction (LVEF) during rest in 135 patients advanced breast cancer. EPI doses were 60 mg/m2 on days 1 8 every 4 weeks or 45 plus vindesine 3 same schedule. median cumulative dose 500 (range, 47 to 1,563). Eight developed congestive heart failure (CHF). Of 67 treated less than mg/m2, none CHF. Among 48 between 1,000 one had CHF (2%; 95% confidence limits, 0.1 11.1). 20 who received from 1,563 seven (35%; 15.4 59.2). Four died due cardiotoxicity. risk at present schedule is considerable above mg/m2. At decreases, below it negligible. For all patients, prevalence 6% sensitivity LVEF high (95%), mainly low incidence more 35% only 64%. specificity maximally 62%. Our results suggest that no value as a predictor for